ALZN Key Statistics, Chart & Performance
The current stock price of ALZN is 2.15 USD. In the past month the price increased by 7.92%. In the past year, price decreased by -78.66%.
ALZN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALZN. When comparing the yearly performance of all stocks, ALZN is a bad performer in the overall market: 94.33% of all stocks are doing better.
ALZN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALZN. The financial health of ALZN is average, but there are quite some concerns on its profitability.
ALZN Financial Highlights
Over the last trailing twelve months ALZN reported a non-GAAP Earnings per Share(EPS) of -5.71. The EPS increased by 90.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -127.12% | ||
| ROE | -147.97% | ||
| Debt/Equity | 0 |
ALZN Forecast & Estimates
8 analysts have analysed ALZN and the average price target is 28.56 USD. This implies a price increase of 1228.37% is expected in the next year compared to the current price of 2.15.
ALZN Ownership
About ALZN
Company Profile
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company is headquartered in Atlanta, Georgia and currently employs 4 full-time employees. The company went IPO on 2021-06-15. The firm is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The firm's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
Company Info
ALZAMEND NEURO INC
480 Peachtree Road Ne, Second Floor, Suite 103
Atlanta GEORGIA US
CEO: Stephan Jackman
Employees: 4
Phone: 18447226333
ALZAMEND NEURO INC / ALZN FAQ
What does ALZAMEND NEURO INC do?
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company is headquartered in Atlanta, Georgia and currently employs 4 full-time employees. The company went IPO on 2021-06-15. The firm is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The firm's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
Can you provide the latest stock price for ALZAMEND NEURO INC?
The current stock price of ALZN is 2.15 USD. The price decreased by -1.38% in the last trading session.
Does ALZAMEND NEURO INC pay dividends?
ALZN does not pay a dividend.
What is the ChartMill rating of ALZAMEND NEURO INC stock?
ALZN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about ALZAMEND NEURO INC (ALZN) stock?
8 analysts have analysed ALZN and the average price target is 28.56 USD. This implies a price increase of 1228.37% is expected in the next year compared to the current price of 2.15.
Should I buy ALZN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALZN.
Can you provide the market cap for ALZAMEND NEURO INC?
ALZAMEND NEURO INC (ALZN) has a market capitalization of 8.17M USD. This makes ALZN a Nano Cap stock.